Study on Using Actimyo Device to Track Progression in Adults with Chronic Inflammatory Demyelinating Polyneuropathy During IV Immunoglobulin Treatment

What this Trial Is About

Researchers are studying patients with Chronic Inflammatory Demyelinating Polyradiculoneuritis CIDP to explore the possibility of predicting disease progression during adjustments to intravenous immunoglobulin IVIg treatment. This academic study plans to include about 40 patients who have CIDP and are undergoing IVIg therapy. The aim is to closely monitor their condition and understand changes over time using various clinical and functional assessments. Participants will be assessed every three months over one year. During each visit, clinical examinations will include measures like the MRC sum score, mISS score, and I-RODS score. Functional tests such as the 6-minute walk test, myogrip measurement, and 9 Hole Peg Test will also be performed. Additionally, participants will wear the Actimyo device daily for one month following each visit. Actimyo is a home-based device consisting of two watch-like sensors that record movement data including acceleration and angular velocity. Throughout the study, researchers will gather data from clinical exams, functional tests, questionnaires, and Actimyo device monitoring to evaluate patients mobility and physical function. The primary outcomes include stride velocity and stride length measurements over one year. The study involves regular evaluations to track disease stability and monitor participants response to IVIg treatment. The total participation time is one year with quarterly visits and continuous device monitoring between visits.

Exploratory Study on Predicting CIDP Patients' Decline During IV Immunoglobulin Treatment Adaptation Feasibility.